Resibufogenin (Synonyms: Bufogenin; Recibufogenin)

Name: Resibufogenin
Brand: MedChemExpress
SKU: HY-N0815
Rating: 5.0 (6 reviews)

Cat. No.: HY-N0815 Purity: 99.93%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Resibufogenin is an orally active anticancer agent. Resibufogenin can be extracted from toad venom. Resibufogenin blocks signaling pathways such as PI3K/Akt, NF-κB, AP-1, activates GSK-3β, and regulates cyclin D1. Resibufogenin can activate central neurons. Resibufogenin has anti-inflammatory activity. Resibufogenin has anti-tumor effects on a variety of tumors such as multiple myeloma, renal cancer, colorectal cancer, pancreatic cancer, and glioma.

For research use only. We do not sell to patients.

Resibufogenin Chemical Structure

CAS No. : 465-39-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Resibufogenin:

Resibufogenin (Standard) Get quote

6 Publications Citing Use of MCE Resibufogenin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All AP-1 Isoform Specific Products:

View All Isoforms

c-Fos c-Jun

View All GSK-3 Isoform Specific Products:

View All Isoforms

GSK-3 GSK-3α GSK-3β

View All CDK Isoform Specific Products:

View All Isoforms

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

GSK-3β

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μM Compound: 6	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 24050254]
HepG2	IC₅₀	43.3 μM Compound: 6	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 24050254]
HL-60	IC₅₀	0.5 μg/mL Compound: 11	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 11575946]
KB	IC₅₀	1.3 μg/mL Compound: 11	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 11575946]
KB	IC₅₀	1.34 μg/mL Compound: 6	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 12141860]
MH60	IC₅₀	> 65.1 μM Compound: 4	Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay	[PMID: 15620253]
MH60	IC₅₀	10 μg/mL Compound: 11	Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay	[PMID: 11575946]
MH60	IC₅₀	10.48 μg/mL Compound: 6	Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay	[PMID: 12141860]
MH60	IC₅₀	22.9 μM Compound: 4	Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6 Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6	[PMID: 15620253]

In Vitro

Resibufogenin (2-8 µM; 12-48 h) inhibits RPMI8226 cell viability in a dose- and time-dependent manner, with an IC₅₀ value of 7.694 µM at 48 h^[1].
Resibufogenin (10 mM) irreversibly activates mitral cells (MCs) in mouse main olfactory bulb (MOB) slices, evoking a lasting increase in depolarization and firing rate, and some cells die^[2].
Resibufogenin (10-200 nM; 12 h) inhibits the growth activity of Caki-1 cells in a dose-dependent manner, with an IC₅₀ value of 408.2 nM^[3].
Resibufogenin (0.1-10 μM; 24-48 h) decreases the cell viability of HCT116 cells dose-dependently^[4].
Resibufogenin (20 μM; 12 h) inhibits the migration of ES-2 and TOV-21G OCCC cells^[5].
Resibufogenin (2-5 μM; 1-3 days) inhibits the growth of human colon cancer HT-29 cells and induces G1-phase arrest in HT-29 cells^[6].
Resibufogenin (20-80 μM; 1 h) suppresses LPS-induced inflammation via inhibiting NF-κB and AP-1 pathways in RAW264.7 cells^[7].
Resibufogenin (1-10 μM; 24-72 h) inhibits the viability of human pancreatic cancer cells Panc-1 and Aspc^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	RPMI8226
Concentration:	2 µM, 4 µM, 8 µM
Incubation Time:	12, 24, 48 h
Result:	Upregulated E-cadherin, downregulated N-cadherin and Vimentin, and reduced the protein expression of p-AKT and p-PI3K in a dose-dependent manner. Did not alter the expression of AKT and PI3K.

In Vivo

Resibufogenin (20 mg/kg; i.p.; daily; 21 days) suppresses the growth of TOV-21G cell tumor xenografts in nude mice, as indicated by a significant decrease in tumor volumes and changes in the expression of Ki-67^[5].
Resibufogenin (5-20 mg/kg; i.p.; 30 min before LPS challenge) ameliorates endotoxemia in ICR mice, as indicated by a significant decrease in serum TNF-α, IL-6 and MCP-1 levels^[7].
Resibufogenin (10-20 mg/kg; i.g.; every day; 20 days) suppresses human pancreatic tumor xenograft growth in athymic nude mice without causing systemic toxicity^[8].
Resibufogenin (10 mg/kg/day; i.p.; daily) exerts antitumor effects in BALB/c nude mice with orthotopic P3#GBM tumor xenografts, prolonging the median survival of tumor-bearing mice and suppressing tumor proliferation^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c-nu/nu mice (female, 18-22 g, 2-month-old) with Aspc xenograft^[8]
Dosage:	10 mg/kg, 20 mg/kg
Administration:	Intragastric injection, every day, 20 days
Result:	Significantly inhibited the growth of Aspc tumor xenografts. Showed mean tumor masses of 0.39 g and 0.21 g at 10 mg/kg and 20 mg/kg, respectively. Increased the phosphorylation levels of PKCα/β and GSK-3β, decreased the phosphorylation level of p65 in tumors. Did not remarkably alter organ indexes, suggesting no systemic toxicity.

Molecular Weight

384.51

Formula

C₂₄H₃₂O₄

CAS No.

465-39-4

Appearance

Solid

Color

White to off-white

SMILES

C[C@]([C@@H](C(C=C1)=COC1=O)C2)(CC[C@@]3([H])[C@@]4([H])CC[C@@]5([H])[C@@]3(CC[C@H](O)C5)C)[C@@]64[C@@H]2O6

Structure Classification

Steroids

Initial Source

Animals

toad

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (260.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6007 mL	13.0036 mL	26.0071 mL
5 mM	0.5201 mL	2.6007 mL	5.2014 mL
10 mM	0.2601 mL	1.3004 mL	2.6007 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.75 mg/mL (7.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.75 mg/mL (7.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.75 mg/mL (7.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.93%

Select Batch:

Data Sheet (302 KB) SDS (479 KB)

COA (253 KB) HNMR (156 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Zhou Y, et al. Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway. Exp Ther Med. 2022 May 13;24(1):441. [Content Brief]

[2]. Wang ZJ, et al. Resibufogenin and cinobufagin activate central neurons through an ouabain-like action. PLoS One. 2014 Nov 24;9(11):e113272. [Content Brief]

[3]. Wu Y, et al. Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1. Biology (Basel). 2024 Dec 19;13(12):1064. [Content Brief]

[4]. Han Q, et al. Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis. J Transl Med. 2018 Jul 20;16(1):201. [Content Brief]

[5]. Zhou G, et al. Resibufogenin inhibits ovarian clear cell carcinoma (OCCC) growth in vivo, and migration of OCCC cells in vitro, by down-regulating the PI3K/AKT and actin cytoskeleton signaling pathways. Am J Transl Res. 2019 Oct 15;11(10):6290-6303. [Content Brief]

[6]. Ichikawa M, et al. Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells. PLoS One. 2015 Jun 29;10(6):e0129851. [Content Brief]

[7]. Gao Y, et al. Resibufogenin, one of bufadienolides in toad venom, suppresses LPS-induced inflammation via inhibiting NF-κB and AP-1 pathways. Int Immunopharmacol. 2022 Dec;113(Pt A):109312. [Content Brief]

[8]. Liu L, et al. Resibufogenin suppresses transforming growth factor-β-activated kinase 1-mediated nuclear factor-κB activity through protein kinase C-dependent inhibition of glycogen synthase kinase 3. Cancer Sci. 2018 Nov;109(11):3611-3622. [Content Brief]

[9]. Zhang X, et al. Resibufogenin Targets the ATP1A1 Signaling Cascade to Induce G2/M Phase Arrest and Inhibit Invasion in Glioma. Front Pharmacol. 2022 May 17;13:855626. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6007 mL	13.0036 mL	26.0071 mL	65.0178 mL
	5 mM	0.5201 mL	2.6007 mL	5.2014 mL	13.0036 mL
	10 mM	0.2601 mL	1.3004 mL	2.6007 mL	6.5018 mL
	15 mM	0.1734 mL	0.8669 mL	1.7338 mL	4.3345 mL
	20 mM	0.1300 mL	0.6502 mL	1.3004 mL	3.2509 mL
	25 mM	0.1040 mL	0.5201 mL	1.0403 mL	2.6007 mL
	30 mM	0.0867 mL	0.4335 mL	0.8669 mL	2.1673 mL
	40 mM	0.0650 mL	0.3251 mL	0.6502 mL	1.6254 mL
	50 mM	0.0520 mL	0.2601 mL	0.5201 mL	1.3004 mL
	60 mM	0.0433 mL	0.2167 mL	0.4335 mL	1.0836 mL
	80 mM	0.0325 mL	0.1625 mL	0.3251 mL	0.8127 mL
	100 mM	0.0260 mL	0.1300 mL	0.2601 mL	0.6502 mL

Resibufogenin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Resibufogenin (Synonyms: Bufogenin; Recibufogenin)

Customer Review

Other Forms of Resibufogenin:

6 Publications Citing Use of MCE Resibufogenin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PI3K Isoform Specific Products:

View All Akt Isoform Specific Products:

View All NF-κB Isoform Specific Products:

View All AP-1 Isoform Specific Products:

View All GSK-3 Isoform Specific Products:

View All CDK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Resibufogenin Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Resibufogenin (Synonyms: Bufogenin; Recibufogenin)

Customer Review

Other Forms of Resibufogenin:

Resibufogenin Related Antibodies

6 Publications Citing Use of MCE Resibufogenin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PI3K Isoform Specific Products:

View All Akt Isoform Specific Products:

View All NF-κB Isoform Specific Products:

View All AP-1 Isoform Specific Products:

View All GSK-3 Isoform Specific Products:

View All CDK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Resibufogenin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Resibufogenin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report